drugset / Trial / NCT05970432
A Clinical Study of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This phase II clinical trials is multicenter, randomized, double-blind, placebo-controlled to assess the effectiveness and safety of TQH2722 injection in the treatment of subjects with moderate to severe atopic dermatitis.
Timeline
- Start
- 2023-06-19
- Primary completion
- 2024-03
- Completion
- 2024-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TQH2722 | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | TQH2722 | Monoclonal antibody | 300 mg | Subcutaneous |
| Subject | TQH2722 | Monoclonal antibody | 450 mg | Subcutaneous |